Maravai LifeSciences Holdings, Inc. (MRVI) Stock Forecast
MRVI analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.11 / 5 from 9 analysts
- Price target
- $8.50 average of analyst targets
- Upside to target
- +25.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.08
- 52-week range
- $2.83 – $9.00
MRVI analyst ratings
9 analystsNumber of analysts at each rating.
MRVI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MRVI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.08 | −$0.04 | −$0.08 | +30.2% | 9 |
| Current fiscal year (2026) | −$0.11 | −$0.15 | −$0.08 | −$0.29 | +63.0% | 9 |
| Next fiscal year (2027) | −$0.10 | −$0.20 | −$0.02 | −$0.11 | +6.3% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MRVI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $43.6M | $42.4M | $45.4M | +4.6% | 9 |
| Current fiscal year (2026) | $211.8M | $210.5M | $213.1M | +14.0% | 9 |
| Next fiscal year (2027) | $224.9M | $218.3M | $229.5M | +6.2% | 9 |
MRVI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MRVI revenue: reported and forecast
MRVI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.09 | −$0.09 | −$0.06 | −$0.06 | +20.0% | 2 up · 4 down |
| Current fiscal year (2026) | −$0.11 | −$0.18 | −$0.18 | −$0.11 | −$0.11 | −5.4% | 6 up · 2 down |
| Next fiscal year (2027) | −$0.09 | −$0.10 | −$0.11 | −$0.10 | −$0.10 | +9.8% | 4 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MRVI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MRVI beat in 6 of 12.
What analysts expect from MRVI
9 analysts cover Maravai LifeSciences; their consensus rating is buy (4.11 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.50, 25.2% above the latest close of $6.79. Analysts expect earnings of −$0.11 per share for 2026, +63.0% from a year earlier. For 2027 the average estimate is −$0.10 per share on revenue of $224.9 million. Maravai LifeSciences beat the EPS estimate in 6 of the last 12 quarters.
Related: MRVI income statement, MRVI key metrics, MRVI chart. See the MRVI stock overview for the latest quote and news.
MRVI forecast FAQ
What is Maravai LifeSciences's price target?
The average analyst price target for Maravai LifeSciences is $8.50, 25.2% above the latest close of $6.79.
Is Maravai LifeSciences a buy, hold or sell?
Of 9 analysts covering Maravai LifeSciences, 5 rate it a strong buy, 0 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Maravai LifeSciences's EPS forecast?
Analysts forecast −$0.11 per share for 2026 (range −$0.15 to −$0.08); for 2027 the estimate is −$0.10.
What is Maravai LifeSciences's revenue forecast?
The average revenue estimate for 2026 is $211.8 million, growth of 14.0%; for 2027 it is $224.9 million.
When does Maravai LifeSciences report earnings?
Maravai LifeSciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.08.
Does Maravai LifeSciences usually beat earnings estimates?
Maravai LifeSciences reported EPS at or above the analyst estimate in 6 of the last 12 quarters.